Dendritic cells ( DCs ) are the major antigen -presenting cells. They are able to present tumor antigens to immunologic effector cells. MHC class II molecules on DC surfaces play an important role in priming effector cells against tumor cells and their antigens. The transactivator CIITA ( MHC class II transactivator ) is a non ± DNA -binding transactivator, which regulates the expression of MHC class II, HLA -DM, and invariant chain and behaves as a master controller of constitutive and inducible MHC class II gene activation. Here, we transfected DCs with the CIITA gene using a novel transfection technique. The vector system consisted of a plasmid bound to an adenovirus via poly -L -lysine, which is covalently bound to a UV -irradiated adenovirus. After transfection, expression of MHC class II on DCs increased from 27% to 75% on day 2 after transfection. Transfected DCs were co -cultured with immunologic effector cells. Cytotoxicity of effector cells against tumor cells increased after co -culture with transfected DCs to 63% compared to 15% with effector cells co -cultured with irrelevantly transfected DCs ( P = .037 ) . This effect was dependent on the timing and period of coculture. In conclusion, transfection of DCs led to an increase in antitumoral immunostimulatory capacity of DCs. We can further conclude that DCs could be efficiently transfected with the CIITA gene. Transfection of DCs led to an increase in antitumoral immunostimulatory capacity of DCs and may have a major impact on immunotherapeutic protocols for patients with cancer.
P reviously, we and others 1 could show a relative resistance of solid tumor cells to immunologic effector cells in vitro. This resistance may be one reason for the experience that these tumors withstand immunotherapeutic approaches in humans.
Dendritic cells (DCs ) may be used to overcome the tumor escape. They play a major role in the immune response to tumor-associated antigens. DCs capture and process antigens in the periphery, express lymphocyte co -stimulatory molecules, migrate to lymphoid organs, and secrete mediators to initiate immune responses. 2 DCs stimulate immunologic effector cells such as T lymphocytes against tumor-associated antigens. Therefore, they represent a powerful tool for manipulating the immune attack against tumor cells. They can be readily obtained in sufficient quantities to allow biologic studies and clinical trials. 3 DCs present tumor antigens to immunologic effector cells. We developed a protocol generating large numbers of efficient cytotoxic effector cells. 4 ± 6 These cell populations include, apart from cytotoxic T cells, up to 20% T cells with NK cell phenotype ( CD3 + CD56 + ) . These NK -like T lymphocytes are generated by incubation of peripheral blood lymphocytes with anti -CD3 monoclonal antibody, interleukin -2, interleukin -1-beta, and interferon-. NKlike T lymphocytes possess an enhanced cytotoxicity and a higher proliferation rate compared to LAK cells. 7 ± 9 
CD3
+ CD56 + NK -like T lymphocytes were originally described in 1986 by Schmidt et al 10 and Lanier et al 11 and further characterized by Ortaldo et al, 12 who showed that these cells are capable of lysing a broad array of tumor targets in a non ±MHC -restricted manner. Despite their high cytotoxic activity against tumor cells, normal human hematopoietic progenitor cells were largely unaffected in a CFU -GM assay. 4 It has been shown that NK -like T lymphocytes are capable of eradicating an established human lymphoma in SCID mice. 13 In contrast, lymphokine -activated killer cells had no effect in this in vivo model.
Regulation of MHC class II expression plays a crucial role in the control of the immune response. In MHC class II -negative cells, MHC class II transactivator ( CIITA ) is necessary for the induction of class II genes by interferonand is sufficient, in the absence of interferon -, to turn on MHC class II expression.
14 Class II molecules trigger a T-cell response against exogenous antigens. Antigenic peptides bind to class II dimers and are presented on the cell surface of APC to CD4 T cells. 15 Co -players of antigen processing are the invariant chain (li ) , MHC encoded DM and DO molecules, and certain proteases. 16 ± 18 The transactivator CIITA (a non ±DNA -binding transactivator, which regulates the expression of MHC class II, HLA -DM, and invariant chain ) behaves as a master controller of constitutive and inducible MHC class II gene activation. 19 The CIITA protein has domains normally associated with transcriptional activators such as acidic and proline-, serine -, and threonine -rich domains, and also contains an unusual and important consensus GTP -binding domain. Recent evidence shows that lack of CIITA results in a closed chromatin structure in the class II MHC promoter. 20 Missing of CIITA in humans leads to a severe immunodeficiency, the bare lymphocyte syndrome. Here, we demonstrate the transfection of the CIITA gene into DCs, which strongly increases MHC class II expression. Transfection of the DCs with CIITA led to an increase in antitumoral immunostimulatory capacity.
MATERIALS AND METHODS

Generation of DCs
Peripheral blood mononuclear cells were isolated from buffy coats or from healthy donors by Ficoll density gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway ). Blood from donors was HLA -A2 positive. Blood was drawn according to our protocol accepted by the local ethics committee. Cells were allowed to adhere in six -well plates at a density of 5Â10 6 cells/mL for 1 hour at 378C in RPMI 1640 with 10% autologous, heatinactivated serum. Nonadherent cells were collected for generating NK -like T cells (see below ) . Adherent cells were cultured in 2 mL RPMI 1640 with autologous, heatinactivated serum, 750 U human GM -CSF and 500 U human IL -4 (Essex Pharma, Nu Èrnberg, Germany ) per milliliter for 7 days.
Generation of NK -like T cells
NK -like T cells were generated as described previously. 5, 6 Briefly, nonadherent Ficoll -separated human peripheral blood mononuclear cells were prepared and grown in RPMI 1640 medium (Gibco BRL, Berlin, Germany ), consisting of 10% fetal calf serum (Gibco BRL ), 25 mM HEPES, 100 U /mL penicillin, and 100 g/ ml streptomycin. On day 0, 1000 U / mL human recombinant IFN -(Boehringer, Mannheim, Germany ) were added. After 24 hours of incubation, 50 ng/mL of an antibody against CD3 (Orthoclone OKT 3, Cilag, Sulzbach, Germany ), 100 U /mL interleukin -1 beta, and 300 U /mL interleukin -2 (Boehringer ) were added. Cells were incubated at 378C in a humidified atmosphere of 5% CO 2 and subcultured every 3 days in fresh complete medium and IL -2 at 3Â10 6 cells/mL.
Co -culturing of NK -like T cells with autologous DCs
NK -like T cells were harvested on day 7 and were cocultured for 7 days with autologous DCs using a stimulator to responder ratio of 1:5. This concentration has been titrated and found to be optimal.
Cell lines
DAN -G (pancreas carcinoma cell line ) and Colo 205 ( colon carcinoma cell line ) were purchased from Deutsche Sammlung fu Èr Mikroorganismen und Zellkultur ( DSMZ, Braunschweig, Germany ). The cells were maintained in RPMI 1640 supplemented with 10% fetal calf serum (PAA, Co Èlbe, Germany ) 100 U / mL penicillin and 100 g/mL streptomycin (Seromed, Ju Èlich, Germany ) .
Cytotoxicity assay
A CytoTox 96 nonradioactive assay (Promega, Madison, WI ) was used to measure cytotoxic activity. This assay is a colorimetric alternative to the 51 Cr-release assay. It quantitatively measures lactate dehydrogenase (LDH ) , which is released upon cell lysis in the same way as 51 Cr is released. Released LDH in culture supernatants was 
Blockage experiments
At the indicated time -points, 20 L monoclonal antibody at a concentration of 25 g /mL ( Becton Dickinson, Heidelberg, Germany ) against MHC molecules was added. As a control, irrelevant antibody against mouse IgG was used.
Flow cytometry
Cells were incubated with the corresponding antibodies for 15 minutes on ice. The cells were then washed with phosphate -buffered saline /1% bovine serum albumin (from PAA and Sigma, respectively ) . Dual -color flow cytometric analysis was performed on a Coulter Epics XL cytometer ( Coulter-Immunotech, Krefeld, Germany ). Data were collected from 30,000 cells and analyzed. DCs were phenotyped with the following monoclonal markers: CD1a, CD80, CD86, HLA -ABC, HLA -DR ( all from Pharmingen, Hamburg, Germany ) , CD83 ( Coulter-Immunotech ), and CMRF -44 ( a kind gift from DNJ Hart, New Zealand ). Negative controls consisted of DCs labeled with mouse IgG (PE /FITC; Pharmingen ). Immunologic effector cells were phenotyped with antibodies against CD3, CD4, CD8, CD16, CD56, HLA -ABC, and HLA -DR (all from Coulter-Immunotech ).
Reverse transcription -polymerase chain reaction ( RT -PCR )
RT-PCR was performed by using RNeasy Kit (Qiagen, Hilden, Germany ) for isolation of RNA from transfected DCs. Translation of RNA into cDNA by reverse transcription and amplification of cDNA were performed by using Superscript one -step RT-PCR kit (Gibco BRL, Karlsruhe, Germany ). The following primers were used: forward primer: 5 H -GAG GCT TAT GCC AATATC GCG -3 H , which binds at + 277 of the insert, and the reverse primer: 5 H -GGG GAC AGA GAA GAC AAA GTC GTA C -3 H , which binds at + 1356 of the insert.
Vectors
For generation of the CIITA expression construct total RNA (Qiagen ) was isolated from interferon -±stimulated K562 cells (200 U / mL, 24 hours ). Human cDNA encoding CIITA was synthesized from total RNA by RT-PCR using Superscript II reverse transcriptase (Gibco BRL, Karlsruhe) and the PCR system (Roche, Mannheim, Germany ) ( CIITA sense primer CGCTGGGATTCCTA-CACAAT, antisense primer: AGGCATGTTCTCTGAG-GACA ). The CIITA coding cDNA fragment (3450 bp ) was inserted into the mammalian expression vector pCR2.1 -Topo by 3 H T overhanging ligation according to the manufacturer's instructions (Invitrogen, deSchelp, Netherlands; Fig 1) .
For determination of transfection efficacy and for mock transfection the vector pcDNA3.1 /HisB /LacZ (Invitrogen ) was used.
Transfection of DCs
Transfection of DCs was performed by using UV-irradiated adenovirus with covalently bounds poly -L -lysine (AdV-PLL ). AdV-PLL was used at a multiplicity of infection ( MOI ) of 80± 100. DNA (100 ng ) was incubated with 4.5 L AdV-PLL and 29.4 L HEPES-buffered saline in the dark. After 30 minutes, 15.1 L poly -L -lysine ( P -2636; Sigma ) was added at a ratio of PLL:DNA of 1.3:1.0 and incubation was continued in the dark for 30 minutes. The AdV-PLL ± DNA complex was added to DCs (5Â10 5 cells) in 1 mL phosphate -buffered saline with magnesium and calcium ( PAA ) and 1% of autologous serum. The sixwell plate was centrifuged for 2 minutes by 200Âg and incubated at 378C and 5% CO 2 . After 2 hours the medium was added, and 2 days after infection, the medium was changed.
Statistical analysis
Unpaired t test was used to analyze for statistical significance. A P value < .05 was considered significant. 
RESULTS
In vitro generation of DCs
DCs were generated from buffy coats using GM -CSF and IL -4 as described in Materials and methods. After 7 days of culture the yield of DCs generated was 25% of the starting PBMC population. Adherent cells showed cytoplasmic processes as described for DCs. DCs expressed 35.0 7.0% of CD83, 50.9 2.9% of HLA -DR, and 85.4 2.9% of HLA -ABC on day 13 as determined by flow cytometry. After co -culturing with immunologic effector cells, the cells formed typical nonadherent clusters ( data not shown ).
Blockage of increase in lysis by antibodies against MHC
NK -like T lymphocytes were co -cultured from days 7 to 14 with DC cultures 7 days of age and cytotoxicity of effector cells was analyzed on day 14. Co -culture of NKlike T cells with DCs led to a significant increase in cytotoxic activity as measured by LDH release assay using DAN -G cells, a pancreas carcinoma cell line, as targets.
For determination of the importance of MHC expression on the surface of DCs, antibodies against MHC molecules were added at different time-points.
The increase in cytotoxic activity of NK -like T cells against DAN -G cells could be blocked by addition of antibody against MHC class I. Addition of antibody against MHC class I resulted in a higher decrease when added at later time -points. Addition of antibody against MHC class I at day 6 resulted in a cytotoxicity of 14.2 6.4% compared to 5.7 4.9% by addition at day 10. Using irrelevant antibody, cytotoxicity was 35.7 0.9% at an effector to target ratio of 20:1.
In contrast, antibody against MHC class II showed maximal decreasing effect when added at early timepoints. Cell lysis decreased from 35.7 0.9% to 20.7 1.0% when antibody was added at day 6. Addition of antibody after day 9 showed no effect (Fig 2 ) . Cell surface expression of markers for adenoviral cell entry on DCs
DCs were stained for surface proteins, which are essential for adenoviral cell entry. Coxsackie adenoviral receptor (CAR ) , integrins CD51 /CD61 and alpha v beta 5 ( v 5 ) increased from 4.9 2.6% on day 0 to 40.6 1.6% on day 6, 13.8 3.7% to 30.5. 9.1%, and 4.5 1.7% to 32.6 2.6% during DC culture, respectively (Fig 3) .
Transfection of DCs with the CIITA gene
DCs were transfected with the CIITA gene using a novel technique. Transfection efficiency was determined using a vector containing -gal. Transfected cells could be visualized as blue cells using X -gal as substrate. Using this technique 43.0 2.9% of DCs could be transfected on day 3 of culture; on day 7 98.0 2.5% were transfected (Fig 4A  and B ) . Using RT-PCR technique with specific primers, mRNA encoding for the CIITA gene could be detected in transfected DCs. Mock -transduced DCs were negative for CIITA mRNA (Fig 5) .
Cell surface marker expression of MHC molecules on DCs
DCs were transduced with the CIITA gene on day 3 and cell surface expression of MHC molecules, important for antigen presentation, was determined by flow cytometry. HLA -DR expression increased significantly after transfection compared to transfection with an irrelevant vector on day 9 of DC generation ( 82.6 1.8% compared to 55.4 3.1% on day 9, P= .046) . In contrast, there was no significant change in HLA -ABC expression (95.9 1.3% compared to 84.5 3.5% on day 9; Fig 6) .
Stimulatory activity of transfected DCs on cytotoxic activity of NK -like T lymphocytes NK -like T lymphocytes were co-cultured from days 7 to 14 with DC cultures 7 days of age, and cytotoxicity of effector cells was analyzed on day 14. Co -culture of NKlike T cells with DCs led to a significant increase in cytotoxic activity as measured in an LDH release assay using DAN -G cells, a pancreas carcinoma cell line, as targets. For example, LDH release in co -cultures was 15.3 8.9% compared to 0% with NK -like T cells alone at an effector to target cell ratio of 20:1 (Fig 7; P= .047) . Transfection of DCs with the CIITA gene and co -culture led to a further increase in cytotoxic activity of NK -like T cells compared to DCs transfected with an irrelevant vector (63.5 27.3% compared to 15.3 8.9%, P= .037; Fig 7) .
Increase of antigen presentation of DCs by co -culturing of DCs with NK -like T cells
Antigen presentation of DCs was measured indirectly by lymphoproliferation. We found an enhanced proliferation of 
DISCUSSION
The aim of the study was to increase the cytotoxic effect of NK -like T cells after co -culture with DCs. NK -like T cells are established effector cells with clinical relevance. 21 Many tumors do not elicit an antigen-specific T-cell response, which may be due to the absence of functional DCs or failure of induction of effector cells in patients with tumor. 2 Recently, DCs have been used in several studies to increase the cytotoxic activity of immunologic effector cells in vitro or in vivo. 22 In animal studies, tumor antigens have been coincubated with DCs in vitro. This strategy can lead to protection against tumors and a reduction in the size of established tumors.
± 26
Recently, we showed that DCs pulsed with CA19 -9 or with CEA are able to increase the cytotoxic effect of immunologic effector cells including NK -like T lymphocytes against colon and pancreatic tumor cells significantly. Regulation of MHC class II expression plays a crucial role in the control of the immune response. This could be shown using effector cells co-cultured with DCs with blocked MHC molecules. Blocking of MHC class II molecules on DCs on early days of co -culture with effector cells led to a decrease in immunostimulatory capacity. These data showed the importance of T-helper cell interaction with MHC class II molecules on DCs. Activated T-helper cells are able to stimulate cytotoxic T cells. 28 The transactivator CIITA behaves as a master controller of constitutive and inducible MHC class II gene activation. Here, we tested the effect of transfection of the CIITA gene in DCs. DCs could be transfected efficiently using a novel method of transfection. 29 CAR and integrin expression, important for adenoviral cell entry, 30 increase during DC generation suggesting that the used vector system penetrates the cell via these receptors as well.
MHC class II expression of DCs increased significantly after CIITA gene transfer. This is not surprising because MHC class II is regulated by CIITA. 17 Accordingly, MHC class I remains unchanged after transfection.
Interestingly, transfection of DCs with the CIITA gene led to an increase in antitumoral immunostimulatory capacity of DCs. Cytotoxic activity of immunologic effector cells increased after co -culture with transfected DCs. Because NK -like T cells are supposed to be non± MHC restricted, 5 we hypothesized that the observed effect that antibodies against MHC can block the increase in cytotoxic activity is caused by cytotoxic T cells in an MHC -restricted manner. However, because the increase in cytotoxic activity could be blocked by antibodies against MHC class I, our data suggest that MHC class II on DC surface cause an activation of CD4 -expressing cells in NK -like T-cell cultures, leading to an activation of CD8 -expressing cells with cytotoxic capacity. Transfection of DCs with the CIITA gene leads to an increase in MHC class II expression. We hypothesize that the observed increase in cytotoxicity is due to strengthened induction of T-helper cells followed by an increased activation of cytotoxic T cells.
DCs pulsed with tumor antigens have been used in several studies. Unfortunately, most tumors have no defined tumor antigens. Immunotherapeutical approaches with DCs transfected with the CIITA gene could be a possibility to induce antitumoral responses in these patients.
